$RNTX News

HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8

Rein Therapeutics Q1 EPS $(0.19) Beats $(0.49) Estimate

Rein Therapeutics shares are trading lower. The company issued an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis.

Rein Therapeutics Enrolled 8 Patients In RENEW Trial

Rein Therapeutics Files Prospectus For 30M Share Offering At ~$1.66/Share

Rein Therapeutics Q4 Adj. EPS $(0.11) Beats $(0.24) Estimate

Rein Therapeutics Doses First Patient In Phase 2 Trial Of LTI-03

Brookline Capital Downgrades Rein Therapeutics to Hold

Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03

Rein Therapeutics Q3 EPS $(0.21) Beats $(0.23) Estimate

Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

Rein Therapeutics Reports Preclinical Results For Inhaled LTI-03 In IPF, Showing Safety And Biomarker Reductions

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Cleared To Resume Phase 2 Study Of LTI-03 For Idiopathic Pulmonary Fibrosis

The FDA Has Lifted The Full Clinical Hold On Rein Therapeutics' Phase 2 RENEW Trial Evaluating LTI-03 In Patients With Idiopathic Pulmonary Fibrosis

Rein Therapeutics shares are trading higher after the company received FDA clearance to resume its U.S. Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Receives Authorization From EMA To Initiate Phase 2 "RENEW" Clinical Trial Of LTI-03 For Treatment Of Idiopathic Pulmonary Fibrosis

Rein Therapeutics Announced FDA Feedback On Clinical Hold For U.S. Phase 2 RENEW Trial Of LTI-03 In IPF; MCH/H Findings Deemed Not Dose-Limiting For 24-Week Protocol Up To 10 Mg/Day